Unit:
Κατεύθυνση Σακχαρώδης Διαβήτης και ΠαχυσαρκίαLibrary of the School of Health Sciences
Author:
Theodoropoulou Alexandra
Supervisors info:
Αναστασία Θανοπούλου, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Τσιούφης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αλέξανδρος Κόκκινος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η επίδραση των αναστολέων συμμεταφορέων νατρίου – γλυκόζης 2 (SGLT2) στους βιοδείκτες στην Καρδιακή Ανεπάρκεια
Translated title:
The effect of sodium-glucose cotransporter 2 inhibitors (SGLT2) on biomarkers in Heart Failure
Summary:
Heart failure (HF) is still a major global health problem with increased mortality and need for hospitalization. Therefore, it is reasonable to constantly seek new therapies in this direction. Sodium-glucose co-transporter 2 inhibitors (SGLT2 Inhibitors) which were presented a few years ago as antidiabetic drugs, have shown from the very first studies, unprecedented benefits in terms of cardiovascular morbidity and mortality and the occurrence of HF in high-risk patients with Diabetes Mellitus (DM). This was the trigger to be at the center of studies for the treatment of HF, even in people without DM. Thus, in the latest guidelines of the European Society of Cardiology, SGLT2i were introduced as first-line drugs for the treatment of HF. In this review, our aim is to investigate whether these indisputable cardiovascular benefits of SGLT2i are reflected in the change in the values of biomarkers used in daily clinical practice for the management of patients with HF.
Main subject category:
Health Sciences
Keywords:
Heart failure, Biomarkers, Sodium-glucose cotransporter 2 inhibitors, Natriuretic peptides, Cardiorenal markers
